Home›Stock Screener›Kimia Biosciences›Financial Statements

Kimia Biosciences Complete Financial Statements

11 Years of Data
2025 - 2015

In FYNone, Kimia Biosciences (KIMIABL) reported revenue ₹127 Cr, net profit ₹9 Cr and EPS ₹1.90, with a net profit margin of 8.3% and ROE of 100.0%. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review KIMIABL price earnings ratio to evaluate earnings-based valuation against sector peers.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 8.33% 2025 data
EBITDA Margin 18.33% 2025 data
Operating Margin 17.00% 2025 data
Return on Assets 9.01% 2025 data
Return on Equity 100.00% 2025 data

Balance Sheet Ratios

Current Ratio 3.95 2025 data
Equity Ratio 9.01% 2025 data
Asset Turnover 1.08 2025 data

KIMIABL Revenue, Net Profit & EBITDA — Year-on-Year Growth

KIMIABL YoY (March 2025 vs Period) — revenue +5.8%, net profit -10.0%, EBITDA -4.5%, expenses +7.1%. Explore KIMIABL value investing to estimate fundamental worth using multiple valuation models.

Revenue Growth
+5.8%
Year-over-Year
Net Profit Growth
-10.0%
Year-over-Year
EBITDA Growth
-4.5%
Year-over-Year
Expense Growth
+7.1%
Year-over-Year
Assets Growth
+11.0%
Year-over-Year
Operating Cash Flow Growth
+40.0%
Year-over-Year
Investing Cash Flow Growth
-150.0%
Year-over-Year
Financing Cash Flow Growth
-30.8%
Year-over-Year

KIMIABL Income Statement — Revenue, EBITDA & Net Profit

Kimia Biosciences revenue ₹127 Cr, EBITDA ₹21 Cr, net profit ₹9 Cr, EPS ₹1.90 (None) — net profit margin 8.3%. For live price, earnings ratios and company overview, see KIMIABL share price screener.

Periods ₹ Crores
Particulars None March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 127 120 107 130 126 135 107 95 77 2 0 2
Expenses 106 99 105 134 124 124 102 88 74 2 4 4
EBITDA 21 22 1 -4 2 11 5 7 3 0 -3 -1
Operating Profit Margin % 15.00% 17.00% 0.00% -4.00% 1.00% 6.00% 4.00% 6.00% 3.00% -67.00% -1759.00% -110.00%
Depreciation 4 3 3 3 3 2 2 1 1 0 0 0
Interest 4 5 5 4 4 3 3 2 1 0 1 0
Profit Before Tax 13 14 -7 -12 -5 6 1 4 2 -1 -4 -2
Tax 0 4 -2 -3 -1 0 0 0 0 0 0 0
Net Profit 9 10 -5 -9 -4 5 1 4 2 -1 -4 -2
Earnings Per Share (₹) 1.90 2.03 -1.12 -1.98 -0.78 1.08 0.33 2.64 1.14 -1.26 -5.49 -2.31

KIMIABL Balance Sheet — Assets, Liabilities & Shareholders' Equity

KIMIABL total assets ₹111 Cr, total equity ₹10 Cr, total liabilities ₹ Cr (2025) — ROE 100.0%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 111 100 121 110 107 86 65 58 12 4 5
Current Assets 75 61 83 73 72 61 48 43 2 1 1
Fixed Assets 33 32 34 35 28 18 16 13 7 3 3
Capital Work in Progress 0 1 1 0 6 6 2 3 3 0 0
Investments 0 0 0 0 0 0 0 0 0 0 0
Other Assets 78 68 87 74 73 62 48 43 2 1 1
LIABILITIES
Total Liabilities
Current Liabilities 19 30 40 33 37 34 29 25 9 7 1
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 10 0 6 15 18 13 6 2 -5 -4 0
Share Capital 5 5 5 5 5 5 2 2 7 7 7
Reserves & Surplus 5 -4 1 10 14 9 2 -2 -12 -11 -7

KIMIABL Cash Flow Statement — Operating, Investing & Financing

Kimia Biosciences operating cash flow ₹21 Cr, investing ₹-5 Cr, financing ₹-17 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities 21 15 -7 8 6 0 -3 -7 -1 -6 0
Investing Activities -5 -2 -3 -1 -14 -9 -2 -2 -6 0 0
Financing Activities -17 -13 10 -8 8 9 4 10 7 6 0
Net Cash Flow 0 0 0 0 0 0 -1 1 0 0 0